medwireNews: A hybrid formulation of cabazitaxel has been supported for use in European patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel chemotherapy.
Cabazitaxel Accord received a recommendation for marketing authorization from the EMA’s Committee for Medicinal Products for Human Use. The agent is now available as a 20 mg/mL concentrate for infusion, following studies demonstrating bioequivalence to reference cabazitaxel, which was approved in 2011 as a 1-hour infusion at a dose of 25 mg/m2.
Both cabazitaxel formulations are for use alongside prednisone or prednisolone.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group